Welcome to Peplin
We are a Phase 3 specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. We are currently developing PEP005 (ingenol mebutate), or PEP005, which is a novel compound derived from Euphorbia peplus, or E. peplus, a rapidly growing, readily-available plant, commonly referred to as petty spurge or radium weed. The sap of E. peplus has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, such as skin cancer and pre-cancerous skin lesions. Peplin has extensive international patent coverage over its technologies.
Company Highlights
Phase 3, Face and Scalp (REGION-IIa and IIb) Positive Results
LEO Pharma announced positive results for its two Phase 3 clinical trials for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK) on head treatment areas, which include the face and scalp. The REGION-IIa and REGION-IIb each achieved their primary and secondary efficacy endpoints with statistically significant clearance of AK lesions vs. vehicle.
LEO Pharma Completes Peplin Acquisition for 287.5m
Peplin has completed its merger with LEO Pharma after obtaining the approval of the majority of Peplin stockholders. The deal was originally announced on 3 September, 2009 when LEO, a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, agreed to acquire all outstanding securities of Peplin for approximately US$287.5 million in cash. Peplin will operate as a US-based LEO subsidiary.
Phase 3 (REGION-I) Positive Results
Peplin announced positive results for PEP005 (ingenol mebutate) Gel in REGION-I, its Australian and US based Phase 3 solar keratosis clinical trial for the treatment of lesions on non-head locations. REGION-I met its primary and secondary efficacy endpoints with statistically significant clearance of AK lesions vs. vehicle. PEP005 Gel is the first topical treatment to demonstrate a statistically significant benefit over vehicle across non-head anatomical locations, including back of hand with the median reduction in overall lesion count equal to 66.7%. The 2nd Phase 3 non-head trial, REGION-Ib, completed enrollment in August 2009.
Sign up to receive email alerts regarding Peplin news and financials here
Quick downloads
Contact us
Clinical trial information
Please refer to: www.clinicaltrials.gov for trial information
Corporate information
Email: info@peplin.com
AUSTRALIA
Street Address
Level 3, Tower One
25 Montpelier Road
Bowen Hills, Queensland 4006
Postal Address
PO Box 3325
Newstead LPO
QLD, 4006, Australia
Telephone: +61-7-3250 1200
Facsimile: +61-7-3250 1299
Email: info@peplin.com
Website: www.peplin.com
